Autologous Cell Therapy Market To Reach $17.97 Billion By 2030

Autologous Cell Therapy Market Growth & Trends

The global autologous cell therapy market size is expected to reach USD 17.97 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 22.20% from 2024 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

 Request a free sample copy or view report summary: Autologous Cell Therapy Market Report

Autologous Cell Therapy Market Report Highlights

• The cancer segment dominated the market and accounted for a share of 29.9% in 2023. According to the American Cancer Society, it is anticipated that 1,958,310 new instances of cancer and 609,820 fatalities due to the disease.

• The bone marrow segment held the largest share of 29.9% in 2023. The bone marrow in autologous cell therapy has been successfully used to treat different diseases.

• The academics & research segment held the largest share of 39.05% in 2023 and is anticipated to grow rapidly from 2024 to 2030.

• North America autologous cell therapy market accounted for 36.68% share in 2023. The market is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics and Bristol Myers Squibb operate in this region.

• Asia Pacific autologous cell therapy market is anticipated to witness fastest growth over the forecast period. owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies.

Autologous Cell Therapy Market Segmentation

Grand View Research has segmented the global autologous cell therapy market report based on application, source, end-use, and region:

Autologous Cell Therapy Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Neurodegenerative disorders

• Cardiovascular disorders

• Autoimmune disorders

• Orthopedics

• Wound healing

• Others

Autologous Cell Therapy Source Outlook (Revenue, USD Million, 2018 - 2030)

• Bone Marrow

• Epidermis

• Mesenchymal stem cells

• Haematopoietic stem cells

• Chondrocytes

• Others

Autologous Cell Therapy End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Ambulatory Centers

• Academics & Research

• Others

Autologous Cell Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players of Autologous Cell Therapy Market

• BrainStorm Cell Therapeutics

• Holostem Terapie Avanzate S.R.L

• Pharmicell Co. Inc

• Opexa Therapeutics

• Caladrius Biosciences Inc

• U.S. Stem Cell Inc

• Lonza

• Bristol Myers Squibb

• Novartis

• Autolus therapeutics

• Tego Science

• Corning Incorporated

• Bio Elpida

• Vericel Corporation

• Catalent, Inc

• Sartorius AG